Publication:
Conjunctival and nasal microflora in patients on topical cyclosporine for dry eye

dc.contributor.authorElibol E. S.
dc.contributor.authorHabip Z.
dc.contributor.authorELBAY A.
dc.contributor.authorCırık A. A.
dc.contributor.authorOğuz H.
dc.contributor.institutionauthorELBAY, AHMET
dc.date.accessioned2024-03-06T21:50:33Z
dc.date.available2024-03-06T21:50:33Z
dc.date.issued2024-01-01
dc.description.abstractIntroduction: Dry eye is a common ocular condition causing discomfort and visual disturbances. Anti-inflammatory agents like Cyclosporine A (CsA) are often used in its treatment. However, the impact of CsA on ocular flora remains understudied. This research aimed to evaluate changes in conjunctival and nasal microflora in patients receiving topical cyclosporine for dry eye. Methods: In this cross-sectional study, conjunctival and nasal samples were collected from two groups of dry eye patients. Group 1 consisted of 38 patients using CsA eye drops, while Group 2 included 34 patients using preservative-free artificial tear drops. Bacterial cultures were grown from the samples, and the identified organisms underwent antibiotic susceptibility testing. Additionally, alpha diversity metrics were employed to assess the diversity of bacterial species in the samples. Results: Bacterial growth was observed in 75% of conjunctival samples and 97.22% of nasal samples. Staphylococcus epidermidis was the predominant organism in both groups. Alpha diversity analysis showed no significant differences in Shannon diversity and OTU richness between the groups for most bacterial species. Antibiotic susceptibility tests revealed no substantial variations in resistance patterns between the groups. Conclusion: This study provides valuable insights into the impact of CsA eye drops on conjunctival and nasal flora in dry eye patients. The findings suggest that CsA does not significantly influence the composition, diversity, or antibiotic resistance patterns of ocular flora. Long-term topical cyclosporine treatment for dry eye does not significantly impact conjunctival microflora or lead to antibiotic resistance. These results have important implications for the safe use of CsA in patients undergoing ocular treatments, particularly those at risk of intraocular infections.
dc.identifier.citationElibol E. S., Habip Z., ELBAY A., Cırık A. A., Oğuz H., "Conjunctival and nasal microflora in patients on topical cyclosporine for dry eye", International Journal of Immunopathology and Pharmacology, cilt.38, 2024
dc.identifier.doi10.1177/03946320241227103
dc.identifier.issn0394-6320
dc.identifier.pubmed38323796
dc.identifier.scopus85184513590
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85184513590&origin=inward
dc.identifier.urihttps://hdl.handle.net/20.500.12645/39131
dc.identifier.volume38
dc.identifier.wosWOS:001157704200001
dc.relation.ispartofInternational Journal of Immunopathology and Pharmacology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectMedicine
dc.subjectPharmacology and Therapeutics
dc.subjectBasic Pharmaceutics Sciences
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectİmmünoloji
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectALERJİ
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectClinical Medicine (MED)
dc.subjectLife Sciences (LIFE)
dc.subjectCLINICAL MEDICINE
dc.subjectIMMUNOLOGY
dc.subjectPHARMACOLOGY & TOXICOLOGY
dc.subjectALLERGY
dc.subjectPHARMACOLOGY & PHARMACY
dc.subjectİmmünoloji ve Alerji
dc.subjectFarmakoloji
dc.subjectImmunology and Allergy
dc.subjectImmunology
dc.subjectPharmacology
dc.subjectconjunctival flora
dc.subjectcyclosporine drops
dc.subjectdry eye
dc.subjectnasal flora
dc.subjectocular infection
dc.titleConjunctival and nasal microflora in patients on topical cyclosporine for dry eye
dc.typeArticle
dspace.entity.typePublication
local.avesis.id99ef0f08-17b5-4d5c-8bd6-8cd08ba29559
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus
relation.isAuthorOfPublication7a25551f-eebe-44b4-8dd9-95bc4f53bac1
relation.isAuthorOfPublication.latestForDiscovery7a25551f-eebe-44b4-8dd9-95bc4f53bac1

Files